Serum paraoxonase and arylesterase activities in iron deficiency anemia during pregnancy;Gebelikte demir eksikliǧi anemisinde serum paraoksanaz ve arilesteraz aktiviteleri

Turkish Journal of Medical Sciences

Volumn 41, Issue 2, 2011, Pages 185-191

  Camuzcuoǧlu, Hakan ^a   Toy, Harun ^a   Vural, Mehmet ^a   Camuzcuoǧlu, Aysun ^b   Taşkin, Abdullah ^a   Çelik, Hakim ^a  

^a HARRAN UNIVERSITY   (Turkey)

^b Sanliurfa Maternity Hospital   (Turkey)

Author keywords

Arylesterase; Iron deficiency anemia; Lipid hydroperoxide levels; Paraoxonase; Pregnancy

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; LIPID PEROXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PATIENT ASSESSMENT; PREGNANT WOMAN; UPREGULATION;

EID: 80855132425     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0904-41     Document Type: Article

References (25)

1. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106: 1335-40.
2. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007; 191: 397-402.
3. Lieberman E, Ryan KJ, Monson RR, Schoenbaum SC. Association of maternal hematocrit with premature labor. Am J Obstet Gynecol 1988; 159: 107-14.
4. Hartfield DS, Lowry NJ, Keene DL, Yager JY. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol 1997; 16: 50-3.
5. Kwik-Uribe CL, Golub MS, Keen CL. Chronic marginal iron intakes during early development in mice alter brain iron concentrations and behavior despite postnatal iron supplementation. J Nutr 2000; 130: 2040-48.
6. Vives Corrons JL, Miguel-Garcia A, Pujades MA, Miguel-Sosa A, Cambiazzo S, Linares M et al. Increased susceptibility of microcytic red blood cells to in vitro oxidative stress. Eur J Haematol 1995; 55: 327-31.
7. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998; 39: 1529-42.
8. Carew TE. Role of biologically modified low-density lipoprotein in atherosclerosis. Am J Cardiol 1989; 64: 18G-22.
9. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1-12.
10. Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
11. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91.
12. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
13. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-35.
14. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-99.
15. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
16. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-95.
17. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999; 300: 58-62.
18. Isler M, Delibas N, Guclu M, Gultekin F, Sutcu R, Bahceci M et al. Superoxide dismutase and glutathione peroxidase in erythrocytes of patients with iron deficiency anemia: effects of different treatment modalities. Croat Med J 2002; 43: 16-9.
19. Jansson LT, Perkkio MV, Willis WT, Refino CJ, Dallman PR. Red cell superoxide dismutase is increased in iron deficiency anemia. Acta Haematol 1985; 74: 218-21.
20. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211: 871-79.
21. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998; 31: 329-36.
22. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-87.
23. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-90.
24. Mackness MI, Durrington PN, Ayub A, Mackness B. Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem Biol Interact 1999; 119-120: 389-97.
25. Merono T, Sorroche P, Rosso LA, Casanas L, Boero LE, Arbelbide JA et al. Proatherogenic disturbances in lipoprotein profile, associated enzymes and transfer proteins in women with iron deficiency anaemia. Clin Biochem 2010; 43: 416-23.